Literature DB >> 21248038

The V1V2 domain and an N-linked glycosylation site in the V3 loop of the HIV-1 envelope glycoprotein modulate neutralization sensitivity to the human broadly neutralizing antibody 2G12.

Antoine Chaillon1, Martine Braibant, Thierry Moreau, Suzie Thenin, Alain Moreau, Brigitte Autran, Francis Barin.   

Abstract

The broadly neutralizing human monoclonal antibody 2G12 binds to a carbohydrate-dependent epitope involving three major potential N-linked glycosylation sites (PNGS) of gp120 (N295, N332, and N392). Through analysis of the sensitivity to 2G12 of pseudotyped viruses carrying envelope proteins from HIV-1 clade B-infected long-term nonprogressors, we selected two naturally occurring env clones with opposite sensitivities to 2G12, albeit harboring the 3 particular PNGS known to be essential for 2G12 binding (N295, N332, and N392). The resistant clone presented a long and potentially heavily glycosylated V1V2 loop and an additional PNGS (N302) in the V3 loop. The sensitive clone harbored a short V1V2 loop and lacked the PNGS at N302. We created chimeric envelope genes by swapping the V1V2 domains of the two env clones. The influence of N302 on 2G12 sensitivity was assessed by PCR-based site-directed mutagenesis. Both the exchange of the V1V2 domain and the introduction of the PNGS at N302 on the 2G12-sensitive clone induced a significant decrease in sensitivity to 2G12. In contrast, the reverse V1V2 exchange and the removal of the PNGS at N302 on the 2G12-resistant clone increased sensitivity to 2G12, confirming the influence of these regions on 2G12 sensitivity. Our results, supported by a molecular-modeling study, suggest that both the V1V2 loop and an additional PNGS in V3 might limit access to the 2G12 epitope.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21248038      PMCID: PMC3067857          DOI: 10.1128/JVI.02424-10

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  38 in total

1.  Multiple alignment of DNA sequences with MAFFT.

Authors:  Kazutaka Katoh; George Asimenos; Hiroyuki Toh
Journal:  Methods Mol Biol       Date:  2009

2.  HIV-1 gp120 determinants proximal to the CD4 binding site shift protective glycans that are targeted by monoclonal antibody 2G12.

Authors:  Maria J Duenas-Decamp; Paul R Clapham
Journal:  J Virol       Date:  2010-07-07       Impact factor: 5.103

3.  Disease progression due to dual infection in an HLA-B57-positive asymptomatic long-term nonprogressor infected with a nef-defective HIV-1 strain.

Authors:  Martine Braibant; Jing Xie; Assia Samri; Henri Agut; Brigitte Autran; Francis Barin
Journal:  Virology       Date:  2010-06-19       Impact factor: 3.616

4.  Inhibition of in vivo HIV infection in humanized mice by gene therapy of human hematopoietic stem cells with a lentiviral vector encoding a broadly neutralizing anti-HIV antibody.

Authors:  Aviva Joseph; Jian Hua Zheng; Ken Chen; Monica Dutta; Cindy Chen; Gabriela Stiegler; Renate Kunert; Antonia Follenzi; Harris Goldstein
Journal:  J Virol       Date:  2010-04-21       Impact factor: 5.103

5.  Evaluating neutralizing antibodies against HIV, SIV, and SHIV in luciferase reporter gene assays.

Authors:  David C Montefiori
Journal:  Curr Protoc Immunol       Date:  2005-01

6.  Characteristics of the env genes of HIV type 1 quasispecies in long-term nonprogressors with broadly neutralizing antibodies.

Authors:  Martine Braibant; Henri Agut; Christine Rouzioux; Dominique Costagliola; Brigitte Autran; Francis Barin
Journal:  J Acquir Immune Defic Syndr       Date:  2008-03-01       Impact factor: 3.731

7.  Measuring HIV neutralization in a luciferase reporter gene assay.

Authors:  David C Montefiori
Journal:  Methods Mol Biol       Date:  2009

8.  Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target.

Authors:  Laura M Walker; Sanjay K Phogat; Po-Ying Chan-Hui; Denise Wagner; Pham Phung; Julie L Goss; Terri Wrin; Melissa D Simek; Steven Fling; Jennifer L Mitcham; Jennifer K Lehrman; Frances H Priddy; Ole A Olsen; Steven M Frey; Phillip W Hammond; Stephen Kaminsky; Timothy Zamb; Matthew Moyle; Wayne C Koff; Pascal Poignard; Dennis R Burton
Journal:  Science       Date:  2009-09-03       Impact factor: 47.728

9.  Maternal neutralizing antibodies against a CRF01_AE primary isolate are associated with a low rate of intrapartum HIV-1 transmission.

Authors:  Tanawan Samleerat; Suzie Thenin; Gonzague Jourdain; Nicole Ngo-Giang-Huong; Alain Moreau; Pranee Leechanachai; Jirapan Ithisuknanth; Karin Pagdi; Pornpun Wannarit; Suraphan Sangsawang; Marc Lallemant; Francis Barin; Martine Braibant
Journal:  Virology       Date:  2009-03-20       Impact factor: 3.616

10.  Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers.

Authors:  Ann J Hessell; Eva G Rakasz; Pascal Poignard; Lars Hangartner; Gary Landucci; Donald N Forthal; Wayne C Koff; David I Watkins; Dennis R Burton
Journal:  PLoS Pathog       Date:  2009-05-15       Impact factor: 6.823

View more
  13 in total

1.  Emergence of a new HIV type 1 CRF01_AE variant in Guangxi, Southern China.

Authors:  Haiyan Zeng; Zhiwu Sun; Shujia Liang; Lingnuo Li; Yanyan Jiang; Wei Liu; Binlian Sun; Jingyun Li; Rongge Yang
Journal:  AIDS Res Hum Retroviruses       Date:  2012-03-13       Impact factor: 2.205

Review 2.  Neutralizing antibodies and control of HIV: moves and countermoves.

Authors:  Ann J Hessell; Nancy L Haigwood
Journal:  Curr HIV/AIDS Rep       Date:  2012-03       Impact factor: 5.071

3.  Conformational Epitope-Specific Broadly Neutralizing Plasma Antibodies Obtained from an HIV-1 Clade C-Infected Elite Neutralizer Mediate Autologous Virus Escape through Mutations in the V1 Loop.

Authors:  Shilpa Patil; Rajesh Kumar; Suprit Deshpande; Sweety Samal; Tripti Shrivastava; Saikat Boliar; Manish Bansal; Nakul Kumar Chaudhary; Aylur K Srikrishnan; Kailapuri G Murugavel; Suniti Solomon; Melissa Simek; Wayne C Koff; Rajat Goyal; Bimal K Chakrabarti; Jayanta Bhattacharya
Journal:  J Virol       Date:  2016-01-13       Impact factor: 5.103

4.  Molecular evolution of the HIV-1 Thai epidemic between the time of RV144 immunogen selection to the execution of the vaccine efficacy trial.

Authors:  Gustavo H Kijak; Sodsai Tovanabutra; Supachai Rerks-Ngarm; Sorachai Nitayaphan; Chirapa Eamsila; Prayura Kunasol; Chirasak Khamboonruang; Prasert Thongcharoen; Chawetsan Namwat; Nakorn Premsri; Michael Benenson; Patricia Morgan; Meera Bose; Eric Sanders-Buell; Robert Paris; Merlin L Robb; Deborah L Birx; Mark S De Souza; Francine E McCutchan; Nelson L Michael; Jerome H Kim
Journal:  J Virol       Date:  2013-04-10       Impact factor: 5.103

5.  Neutralizing capacity of monoclonal antibodies that recognize peptide sequences underlying the carbohydrates on gp41 of simian immunodeficiency virus.

Authors:  José M Martinez-Navio; Ronald C Desrosiers
Journal:  J Virol       Date:  2012-09-19       Impact factor: 5.103

6.  Kinetic mechanism for HIV-1 neutralization by antibody 2G12 entails reversible glycan binding that slows cell entry.

Authors:  Emily J Platt; Michelle M Gomes; David Kabat
Journal:  Proc Natl Acad Sci U S A       Date:  2012-04-30       Impact factor: 11.205

7.  Recent advances on the use of structural biology for the design of novel envelope immunogens of HIV-1.

Authors:  Shi-Hua Xiang
Journal:  Curr HIV Res       Date:  2013-09       Impact factor: 1.581

8.  Identification of an HIV-1 clade A envelope that exhibits broad antigenicity and neutralization sensitivity and elicits antibodies targeting three distinct epitopes.

Authors:  Simon Hoffenberg; Rebecca Powell; Alexei Carpov; Denise Wagner; Aaron Wilson; Sergei Kosakovsky Pond; Ross Lindsay; Heather Arendt; Joanne Destefano; Sanjay Phogat; Pascal Poignard; Steven P Fling; Melissa Simek; Celia Labranche; David Montefiori; Terri Wrin; Pham Phung; Dennis Burton; Wayne Koff; C Richter King; Christopher L Parks; Michael J Caulfield
Journal:  J Virol       Date:  2013-03-06       Impact factor: 5.103

Review 9.  Neutralizing antibodies to HIV-1 induced by immunization.

Authors:  Laura E McCoy; Robin A Weiss
Journal:  J Exp Med       Date:  2013-02-11       Impact factor: 14.307

10.  Forced virus evolution reveals functional crosstalk between the disulfide bonded region and membrane proximal ectodomain region of HIV-1 gp41.

Authors:  Ashraf I Khasawneh; Annemarie Laumaea; David N Harrison; Anna K Bellamy-McIntyre; Heidi E Drummer; Pantelis Poumbourios
Journal:  Retrovirology       Date:  2013-04-23       Impact factor: 4.602

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.